39 related articles for article (PubMed ID: 24794107)
1. Discovery of novel, non-acidic mPGES-1 inhibitors by virtual screening with a multistep protocol.
Noha SM; Fischer K; Koeberle A; Garscha U; Werz O; Schuster D
Bioorg Med Chem; 2015 Aug; 23(15):4839-4845. PubMed ID: 26088337
[TBL] [Abstract][Full Text] [Related]
2. Novel 1,3,4-oxadiazole derivatives as highly potent microsomal prostaglandin E
Gür Maz T; Dahlke P; Gizem Ergül A; Olğaç A; Jordan PM; Çalışkan B; Werz O; Banoglu E
Bioorg Chem; 2024 Jun; 147():107383. PubMed ID: 38653151
[TBL] [Abstract][Full Text] [Related]
3. Rotational constriction of curcuminoids impacts 5-lipoxygenase and mPGES-1 inhibition and evokes a lipid mediator class switch in macrophages.
Rao Z; Caprioglio D; Gollowitzer A; Kretzer C; Imperio D; Collado JA; Waltl L; Lackner S; Appendino G; Muñoz E; Temml V; Werz O; Minassi A; Koeberle A
Biochem Pharmacol; 2022 Sep; 203():115202. PubMed ID: 35932797
[TBL] [Abstract][Full Text] [Related]
4. Novel human mPGES-1 inhibitors identified through structure-based virtual screening.
Hamza A; Zhao X; Tong M; Tai HH; Zhan CG
Bioorg Med Chem; 2011 Oct; 19(20):6077-86. PubMed ID: 21920764
[TBL] [Abstract][Full Text] [Related]
5. Preserving vascular prostacyclin levels by microsomal prostaglandin E(2) synthase isoform 1 inhibition: a new strategy for vasoprotection?
Krötz F
J Thromb Haemost; 2007 Jul; 5(7):1409-10. PubMed ID: 17488348
[No Abstract] [Full Text] [Related]
6. Design and synthesis of new dihydropyrimidine/sulphonamide hybrids as promising anti-inflammatory agents via dual mPGES-1/5-LOX inhibition.
Al-Wahaibi LH; Elshamsy AM; Ali TFS; Youssif BGM; Bräse S; Abdel-Aziz M; El-Koussi NA
Front Chem; 2024; 12():1387923. PubMed ID: 38800576
[TBL] [Abstract][Full Text] [Related]
7. Clinical data mining reveals analgesic effects of lapatinib in cancer patients.
Zhou S; Zheng F; Zhan CG
Sci Rep; 2021 Feb; 11(1):3528. PubMed ID: 33574423
[TBL] [Abstract][Full Text] [Related]
8. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.
Zhou S; Zhou Z; Ding K; Yuan Y; Loftin C; Zheng F; Zhan CG
Sci Rep; 2020 Jun; 10(1):10187. PubMed ID: 32576928
[TBL] [Abstract][Full Text] [Related]
9. Recent development of lipoxygenase inhibitors as anti-inflammatory agents.
Hu C; Ma S
Medchemcomm; 2018 Feb; 9(2):212-225. PubMed ID: 30108915
[TBL] [Abstract][Full Text] [Related]
10. Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type mice as a new generation of anti-inflammatory drugs.
Ding K; Zhou Z; Hou S; Yuan Y; Zhou S; Zheng X; Chen J; Loftin C; Zheng F; Zhan CG
Sci Rep; 2018 Mar; 8(1):5205. PubMed ID: 29581541
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of human mPGES-1 from structure-based computational screening.
Zhou Z; Yuan Y; Zhou S; Ding K; Zheng F; Zhan CG
Bioorg Med Chem Lett; 2017 Aug; 27(16):3739-3743. PubMed ID: 28689972
[TBL] [Abstract][Full Text] [Related]
12. Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors.
Xia Z; Yan A
Mol Divers; 2017 Aug; 21(3):661-675. PubMed ID: 28484935
[TBL] [Abstract][Full Text] [Related]
13. Computer modeling in predicting the bioactivity of human 5-lipoxygenase inhibitors.
Zhang M; Xia Z; Yan A
Mol Divers; 2017 Feb; 21(1):235-246. PubMed ID: 27904990
[TBL] [Abstract][Full Text] [Related]
14. Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1.
Shang E; Wu Y; Liu P; Liu Y; Zhu W; Deng X; He C; He S; Li C; Lai L
Bioorg Med Chem Lett; 2014 Jun; 24(12):2764-7. PubMed ID: 24794107
[TBL] [Abstract][Full Text] [Related]
15. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
Liedtke AJ; Keck PR; Lehmann F; Koeberle A; Werz O; Laufer SA
J Med Chem; 2009 Aug; 52(15):4968-72. PubMed ID: 19719242
[TBL] [Abstract][Full Text] [Related]
16. Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2 , cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin E synthase-1.
Ahmad W; Kumolosasi E; Jantan I; Bukhari SN; Jasamai M
Chem Biol Drug Des; 2014 Jun; 83(6):670-81. PubMed ID: 24406103
[TBL] [Abstract][Full Text] [Related]
17. Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
Hanke T; Dehm F; Liening S; Popella SD; Maczewsky J; Pillong M; Kunze J; Weinigel C; Barz D; Kaiser A; Wurglics M; Lämmerhofer M; Schneider G; Sautebin L; Schubert-Zsilavecz M; Werz O
J Med Chem; 2013 Nov; 56(22):9031-44. PubMed ID: 24171493
[TBL] [Abstract][Full Text] [Related]
18. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer.
Rådmark O; Samuelsson B
J Intern Med; 2010 Jul; 268(1):5-14. PubMed ID: 20497297
[TBL] [Abstract][Full Text] [Related]
19. Identification and development of mPGES-1 inhibitors: where we are at?
Chang HH; Meuillet EJ
Future Med Chem; 2011 Nov; 3(15):1909-34. PubMed ID: 22023034
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
